Nurgalieva, A.Kh.,
Petrova, Sabina G.,
Gallyamova, Lilia F.,
Ekomasova, Natalia V.,
Sakaeva, Dina D.,
Fedorova, Yulia Yu,
Dzhaubermezov, Murat A.,
Abdeev, Rustem R.,
Rakhimov, Radmir R.,
Khusnutdinova, Elza K.,
Prokofyeva, Darya S. (2025) of this study was to compare the prevalence of
mutations in the BRCA1 (c.68_69delAG, c.4035delA, c.5266dupC, c
Coignard, J.,
Lush, M.,
Beesley, J.,
O’Mara, T.A.,
Dennis, J,
Tyrer, J.P.,
Barnes, D.R.,
McGuffog, L.,
Leslie, G.,
Bolla, M.K.,
Adank, M.A.,
Kiiski, J.I.,
Nevanlinna, H.,
team of authors (2021) Breast cancer (BC) risk for BRCA1 and BRCA2
mutation carriers varies by genetic and familial
Gilyazova, I.R.,
Yankina, M.A.,
Kunsbaeva, G.B.,
Klimentova, E.A.,
Izmaylov, A.A.,
V.N. Pavlov,
Khusnutdinova, E.K. (2016) are presented. DNA was isolated from the peripheral blood as well as
healthy and tumor prostate tissue from each
NIKITIN, A.G.,
CHUDAKOVA, D.A.,
ENIKEEV, R.F.,
GORDIEV, M.G.,
SAKAEVA, D.,
DRUZHKOV, M.,
SHIGAPOVA, L.H.,
BROVKINA, O.I.,
SHAGIMARDANOVA, E.I.,
GUSEV, O.A. (2020) that LS-
mutations are present in patients with hereditary BC more frequently than in
healthy donors
Nurgalieva, A.,
Galliamova, L.,
Ekomasova, N.,
Yankina, M.,
Sakaeva, D.,
Valiev, R.,
Prokofyeva, D.,
Dzhaubermezov, M.,
Fedorova, Y.,
Khusnutdinov, S.,
Khusnutdinova, E. (2023) sequencing (WES) was performed on 18 DNA samples from adenocarcinoma specimens and non-tumor-bearing
healthy